Rehabilitation services remain important in multiple sclerosis

EDITOR—Taylor's enthusiasm for the proposed “sale or return” arrangement for interferon beta seems ill informed.1 Given the variability of multiple sclerosis over time in individual patients, how is the success of treatment to be judged? Using historical controls, such as the Canadian cohort, requires the availability of detailed data to match controls to the current treatment criteria.2

In making these choices, quality adjusted life years and similar utility measures are all we have, flawed as they are. A better debate is over the cut-off …